Autosomal Dominant Hypocalcemia

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BridgeBio Pharma
BridgeBio PharmaCA - Palo Alto
1 program
ADH1 and ADH2 Disease Monitoring Study (DMS)N/A1 trial
Active Trials
NCT05227287Active Not Recruiting95Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
BridgeBio PharmaADH1 and ADH2 Disease Monitoring Study (DMS)

Clinical Trials (1)

Total enrollment: 95 patients across 1 trials

NCT05227287BridgeBio PharmaADH1 and ADH2 Disease Monitoring Study (DMS)

ADH1 and ADH2 Disease Monitoring Study (DMS)

Start: Jan 2022Est. completion: Dec 202895 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space